AI Drug Lowers Biological Age
AI-designed lung drug shows potential to lower predicted biological age markers in trial.
Anonymous
Key Points
1
The secondary analysis examined 2,841 proteins from blood samples collected at baseline and at weeks 2, 4 and 12; the results were calibrated against 55,319 protein profiles from the UK Biobank. Of the 71 participants in the original Phase 2a trial, 42 consented to this proteomic analysis.
2
At the 60 mg dose, patients’ mean forced vital capacity increased by 98.4 mL over 12 weeks, while the placebo group declined by 20.3 mL—one of the clearest reported measures of the drug’s lung-function effect.
3
Insilico identified TNIK as a target through its PandaOmics platform and generated rentosertib’s molecular structure with its Chemistry42 system. TNIK is implicated in signaling pathways linked to fibrosis, including TGF-β and Wnt.
4
Vadim Gladyshev of Harvard Medical School, whose aging clock was among those used, called the findings the most convincing evidence so far for a reduction in predicted biological age, while stressing that the participant count was small and aging clocks are imperfect predictors.
5
The disease context is severe: idiopathic pulmonary fibrosis progressively scars and thickens lung tissue, impairing oxygen exchange and often leading to death within a few years of diagnosis. The existing approved drugs, nintedanib and pirfenidone, generally slow functional decline rather than restore lung capacity.
An AI-designed drug called rentosertib, created by Insilico Medicine to treat a fatal lung disease, showed an unexpected effect in a small trial: patients appeared biologically younger after 12 weeks of treatment eWeek. Six independent aging clocks—tools that estimate biological age from blood proteins—all pointed the same direction. The strongest signal suggested patients aged roughly three years backward, though researchers stress this does not prove the drug actually slows aging in healthy people Medical Daily.
The finding marks the first time an AI-discovered drug has shown consistent shifts in biological-age markers in a clinical trial TechSpot. The drug targets a protein called TNIK, which is involved in lung scarring and cellular aging. Idiopathic pulmonary fibrosis, the disease rentosertib was designed to treat, progressively scars the lungs and typically kills patients within a few years of diagnosis TheRundown.ai.
How Six Aging Clocks Detected Biological Youth
Researchers analyzed 2,841 blood proteins from 42 trial participants at baseline and at weeks 2, 4, and 12 Medical Daily. They compared these samples against 55,319 protein profiles from the UK Biobank to calibrate six separate aging-prediction models. All six clocks independently reported the same pattern: rentosertib-treated patients showed biological-age reductions of 2.7 to 3.5 years at 12 weeks, with some measures suggesting effects as large as six years eWeek.
Vadim Gladyshev of Harvard Medical School, who developed one of the aging clocks, called the consensus across independent models "the most convincing evidence so far" for reduced predicted biological age TheRundown.ai. However, he and other experts cautioned that the 42-patient sample is tiny and that aging clocks are imperfect predictors of real health outcomes Medical Daily.
The Lung Drug Also Improved Breathing Function
Beyond the aging-clock signal, rentosertib improved a direct measure of lung capacity. At the 60 mg daily dose, patients' forced vital capacity—the amount of air lungs can hold—increased by 98.4 mL over 12 weeks Medical Daily. The placebo group, by contrast, declined by 20.3 mL, showing the disease's natural progression eWeek.
This lung-function improvement is significant because existing approved drugs for idiopathic pulmonary fibrosis, such as nintedanib and pirfenidone, typically only slow decline rather than restore capacity TheRundown.ai. The Phase 2a trial included just 71 participants across 21 Chinese sites, making it preliminary but encouraging TechSpot.
Why Improved Lungs Do Not Yet Mean Slower Aging
Scientists caution that the younger biological-age readings may simply reflect reduced lung inflammation and scarring, not systemic anti-aging effects eWeek. When lung damage improves, blood proteins tied to fibrosis drop naturally. Because aging clocks are built from blood-protein patterns, they shift toward younger estimates when those disease markers improve Medical Daily.
To prove rentosertib actually slows aging in healthy people or people without lung disease, researchers would need to test the drug in those populations and measure durable outcomes like physical function, hospitalizations, or lifespan TheRundown.ai. The current trial simply does not answer whether the drug extends life or restores youth-like function beyond the damaged lungs TechSpot.
Phase 3 Trial Will Test Lung Benefits in Larger Group
Insilico Medicine has advanced rentosertib to a roughly 320-patient Phase 3 trial in China to confirm its lung-disease benefits Medical Daily. This larger trial is designed to strengthen evidence that the drug genuinely helps idiopathic pulmonary fibrosis patients, but it is not intended as a test of general anti-aging effects eWeek.
The drug was discovered entirely by artificial intelligence—Insilico's PandaOmics platform identified TNIK as a target, and the Chemistry42 system generated rentosertib's molecular structure TechSpot. If Phase 3 succeeds, the company may use the lung indication as a "gateway" to explore TNIK inhibitors in other age-related diseases TheRundown.ai.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
34
Articles
24
Reach
58
A
AnonymousAuthor
